article Advancing FLIP inhibitors for the treatment of NSCLC 26 April 2016 | By Victoria White, Drug Target Review In an exclusive interview, Trevor Perrior, Research Director at Domainex, discusses the cell death regulatory protein FLIP and the potential of FLIP inhibitors as a treatment for NSCLC...
news Queen’s University Belfast and Domainex secure award to advance FLIP inhibitor 26 April 2016 | By Victoria White, Digital Content Producer Queen’s University Belfast and Domainex have secured an award to advance therapeutic candidate molecules into clinical evaluation for treatment of NSCLC...
news Johnson Matthey and Domainex collaborate to provide small molecule discovery services 19 April 2016 | By Victoria White, Digital Content Producer Johnson Matthey and Domainex have announced a collaboration to provide integrated small molecule pharmaceutical discovery and development services...
news Leicester’s Dr Echalier awarded Domainex’s Discovery STAR AWARD 3 February 2016 | By Victoria White This award will give Dr Echalier access to the drug discovery capabilities of Domainex in support of her research...
news Domainex and Cresset form drug discovery services alliance 25 January 2016 | By Victoria White The alliance will give clients access to the expertise of Domainex in protein expression, biochemical assays, hit identification, computational and medicinal chemistry; and to Cresset’s approach to hit identification and drug design...
news Domainex expands its drug discovery service business 29 October 2015 | By Victoria White Domainex is expanding all aspects of its drug discovery service business including biology, analytical chemistry and medicinal chemistry...
news Domainex and ICL team up to discover myocardial infarction therapies 20 October 2015 | By Victoria White Domainex has been selected as Imperial’s strategic drug discovery partner to provide services including biochemical and biophysical assay development...
news Auspherix and Domainex expand antibiotics partnership 15 September 2015 | By Since initiating the project in 2014, significant progress has been made towards the invention of new compounds with activity against both gram-positive and gram-negative bacteria...
news Domainex granted US and EU patents for its lead programme, targeting IKK epsilon and TBK1 11 May 2015 | By Victoria White US and EU Patent Offices have granted Domainex patents for the first generation of inhibitor compounds in its lead programme targeting IKK epsilon and TBK1.
news ZoBio and Domainex join forces to deliver crucial drug target information to support FORMA therapeutics’ drug discovery programs 10 December 2014 | By ZoBio and Domainex ZoBio (Leiden, The Netherlands) and Domainex Ltd. (Cambridge, UK) announce a collaboration with FORMA Therapeutics (Watertown, MA, USA) to provide NMR-based structural biology services for a substantial panel of FORMA drug targets...
news Auspherix and Domainex announce collaboration to develop new drugs to treat antibiotic-resistant bacterial infections 15 October 2014 | By Domainex Domainex Ltd. and Auspherix Pty Ltd announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate...
news Domainex reports success of its lead compound in pre-clinical model of COPD and secures £1.4m Biomedical Catalyst Award 9 July 2014 | By Domainex Domainex Ltd announced that its lead compound has demonstrated a more potent effect in a key model of chronic obstructive pulmonary disease than either roflumulast or a p38 inhibitor...